Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) --

马萨诸塞州沃特敦，2025年4月24日（环球新闻社）--

Kymera Therapeutics, Inc.

凯米拉治疗公司

(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases.

（纳斯达克股票代码：KYMR），一家致力于推进一类新型口服小分子降解剂药物用于免疫疾病的临床阶段生物制药公司，今日宣布将于2025年5月9日星期五东部时间上午10:00至11:30举办视频网络直播。公司将会报告2025年第一季度的财务业绩，并披露其针对多种自身免疫和风湿病的高价值未开发靶点的全新口服开发候选药物。

Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline..

此外，公司还将回顾其行业领先的免疫学管道的亮点和即将到来的里程碑。

To join the video call or view the livestreamed webcast, please register via this

要加入视频通话或观看直播的网络直播，请通过此链接注册

link

链接

, or visit “

，或者访问“

News and Events

新闻与事件

” in the Investors section of the Company’s website at

“在公司网站的投资者部分

www.kymeratx.com

www.kymeratx.com

. A replay of the webcast will be archived and available following the event.

网络直播的重播将在活动结束后存档并提供。

About Kymera Therapeutics

关于凯米拉治疗学

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

Kymera是一家处于临床阶段的生物技术公司，率先在靶向蛋白降解（TPD）领域开发药物，以解决关键的健康问题，并有潜力显著改善患者的生活。Kymera正利用TPD来应对传统疗法无法触及的疾病靶点和通路。

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Kymera已将首款降解剂推进至免疫疾病领域的临床阶段，目前正专注于构建一条行业领先的口服小分子降解剂管线，旨在为这些疾病的患者提供新一代便捷且高效的治疗方案。Kymera成立于2016年，过去几年一直被评为波士顿最佳工作场所之一。

For more information about our science, pipeline and people, please visit .

如需更多关于我们科学、研发管线及人员的信息，请访问。

www.kymeratx.com

www.kymeratx.com

or follow us on

或关注我们

X

X

or

或

LinkedIn

领英

.

。

Availability of Other Information About Kymera Therapeutics

关于Kymera Therapeutics的其他信息的可用性

For more information, please visit the Kymera website at

欲了解更多信息，请访问 Kymera 网站：

https://www.kymeratx.com/

https://www.kymeratx.com/

or follow Kymera on

或关注 Kymera 在

X (@KymeraTx)

X (@KymeraTx)

and

和

LinkedIn (Kymera Therapeutics

领英 (Kymera Therapeutics)

). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on

). 投资者及其他人士应注意，Kymera通过公司网站与其投资者和公众进行沟通，包括但不限于公司披露、投资者报告、常见问题解答、证券交易委员会（SEC）文件和新闻稿，以及在

X

X

and

和

LinkedIn

领英

. The information that Kymera posts on its website or on

。Kymera在其网站上发布的信息或在

X

X

or

或

LinkedIn

领英

could be deemed to be material information. As a result, the Company encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera’s website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended..

可能被视为重要信息。因此，公司鼓励投资者、媒体及其他感兴趣的人士定期查阅 Kymera 在该处发布的信息。Kymera 的网站或社交媒体内容不得视为通过引用并入任何根据修订后的《1933 年证券法》提交的文件中。

Investor and Media Contact:

投资者和媒体联系人：

Justine Koenigsberg

朱斯廷·科尼格斯伯格

Vice President, Investor Relations

投资者关系副总裁

investors@kymeratx.com

投资者@凯默拉公司.com

media@kymeratx.com

media@kymeratx.com

857-285-5300

857-285-5300